PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32652753-0	2020	Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.	Crizotinib	110-120	golgi associated PDZ and coiled-coil motif containing	Homo sapiens	87-91	
34076666-14	2021	The repurposing of crizotinib for GOPC-ROS1 Spitz nevi defines a new treatment option for these lesions, particularly in cases for which surgery is relatively contraindicated.	Crizotinib	19-29	golgi associated PDZ and coiled-coil motif containing	Homo sapiens	34-38	
34875133-14	2022	ROS1 fusions (CEP85L-ROS1 and GOPC-ROS1), identified in 8% of patient cfDNA, might be targeted by crizotinib, entrectinib or larotrectinib.	Crizotinib	98-108	golgi associated PDZ and coiled-coil motif containing	Homo sapiens	30-39	
29935846-0	2018	GOPC-ROS1 Rearrangement as an Acquired Resistance Mechanism to Osimertinib and Responding to Crizotinib Combined Treatments in Lung Adenocarcinoma.	Crizotinib	93-103	golgi associated PDZ and coiled-coil motif containing	Homo sapiens	0-9